Thermo Fisher Scientific completes sale of its microbiology business

This article was originally posted on Chemical Engineering Online.

Summary

Thermo Fisher Scientific has completed the sale of its microbiology business to Astorg, a pan-European private equity firm, for about $1.075 billion, including cash and a $50 million seller note. The divested unit provides antimicrobial susceptibility testing and culture media solutions for clinical and pharmaceutical applications.

What impact do you think this divestiture will have on competition and innovation in clinical microbiology testing?

Thermo Fisher Scientific Inc. (Waltham, Mass.) announced that it has completed the sale of its microbiology business to Astorg, a leading pan-European private equity firm, for consideration of approximately $1.075 billion, consisting of cash and a $50 million seller note. The microbiology business provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and […]

The post Thermo Fisher Scientific completes sale of its microbiology business appeared first on Chemical Engineering.

Thermo Fisher Scientific completes sale of its microbiology business

Related Conversations

Thermo Fisher Scientific to sell its microbiology business as Astorg

Thermo Fisher Scientific opens bioprocess design center in Massachusetts

Elementis completes sale of its pharmaceutical manufacturing business

Merck to acquire U.S.-based Bio-Techne Corp. for $11.3 billion

Thermo Fisher Scientific and NVIDIA collaborating to scale AI-based laboratory automation

Recent Conversations

MBMA Releases New Lunch and Learn Course

STV Selected for Modernization of SFO’s Superbay Hangar

Outokumpu inaugurates biocoke agglomeration plant to reduce ferrochrome CO2 emissions

BioBTX breaks ground on world’s first commercial-scale plant to convert mixed plastic waste to aromatics